App helps cancer patients extend life

OTCINACTION

Scientists have discovered a new medical intervention that can extend the lives of cancer sufferers by a number of months. The discovery is not a novel drug or therapy, it is an app. Patients who reported their symptoms via a tablet survived for five months longer than those who did not, according to a large study which was presented at the world’s biggest oncology meeting yesterday.

The research highlighted the role that cheap and simple tech can play in providing healthcare at a time when drug makers are suffering controversy for the ever-rising cost of prescribed medicines.

Patients were told to report 12 symptoms such as sleeping and breathing difficulties using the app, which was referred to as an electronic patient report system or ePro. If patients took a turn for the worse, an automatic push notification was sent to alert a doctor or nurse. “The system proactively monitored symptoms, so that the care team was able to intervene earlier and catch things before they became more severe,” said Dr Ethan Basch, an oncologist and professor at the University of North Carolina, who led the trial.

cancer_opener_0.jpg

Dr Basch said patients using the app were able to stay on chemotherapy “for substantially longer” than others because they were less likely to turn up to the hospital in a weak state and as a repercussion, not be strong enough to handle the punishing treatment. The ePro patients were also less likely to be admitted to hospital, meaning they did not become bed-bound or acquire an infection like C. difficile while on the ward.

Oncologists have long believed that ePro apps can improve a person’s quality of life, but this is the first time that is has been proven to boost survival in a large number of patients with a broad and varied range of cancers. Patients who used the purpose-built app typically survived for 31 months versus 26 months for those who did not, according to the research, which was unveiled at the annual meeting of the American Society of Clinical Oncology (Asco).

Pfizer unveils antimicrobial ATLAS

OTCINACTION

Last week Pfizer announced the launch of the their Antimicrobial Testing Leadership and Surveillance (ATLAS) website. The site is designed to supply physicians and the global health community with easy access to crucial data on the efficacy of numerous antibiotic treatments and emerging resistance patterns across more than 60 countries.

The interpretation of evolving bacterial resistance patterns is a key development in the process of understanding and managing the rise of antimicrobial resistance. Putting this into perspective, ATLAS can not only help physicians select the most appropriate treatment choices for their patients but also enable global health authorities to develop data-driven antimicrobial resistance mitigation strategies.

Pfizer officially unveiled ATLAS at the European Congress of Clinical Microbiology and Infectious Disease (ECCMID) in Vienna last Saturday. With smartphones and tablets providing such benefits for healthcare professionals these days, Pfizer also offers ATLAS as a mobile app to enable speedy access to vital resistance information during patient care.

1200x630bb

The application works as an interactive platform allowing physicians to evaluate data, conduct analyses and export tables and figures that include parameters such as pathogen, region, specimen source and in vitro susceptibility data.

Another great benefit is that the database is updated every six months with new resistance data from healthcare institutions in over 60 countries.

Dr Freda Lewis-Hall, Chief Medical Officer of Pfizer, said the database was “an important aspect for physicians when treating patients”, adding that “knowledge of where certain resistant bacterial infections tend to occur and knowledge of which antibiotics remain effective against them”. The CMO further added: “ATLAS underscores our continued commitment to providing patients and physicians with meaningful resources that can help ensure appropriate utilisation of antibiotics and improve infection prevention and control.”

#NHOTC17: Day 2

OTCINACTION

This week we publish our second and final blog update on our 28th European OTC INSIGHT conference, which took place in Munich earlier this month and was centred on the theme of Making the Most of New Technology. Below is a quick round-up of proceedings on Day 2.

IMG_2162

Ed Rowland opens Day 2 proceedings

Ed Rowland opened the conference with an update on key drivers and dynamics in the US OTC strategic landscape. Akhil Chandra of Reckitt Benckiser led us into our final networking hour with a discussion on what makes an iconic brand in a world of biosimilar products. Chandra based his talk around the “iconicity” of Nurofen, insisting that when it comes to brands we should challenge the tendency to default, and instead create, identify and nurture iconic / symbolic elements.

Following an hour of networking with OTC peers, our delegates returned for our final session with Jesus Carrasco, Head of Healthcare at Société Générale, who discussed consolidation and the increasing attractiveness of the consumer healthcare industry from a corporate and investor perspective.

Screen Shot 2017-04-24 at 12.02.28

Thornsten Umland from Bayer gave the final presentation on strategic growth and how to build OTC businesses and brands via well executed acquisition and true product innovation.

And finally, a personal message from Nicholas: “Thank you all for making a brilliantly successful conference, the array of speakers and topics covered have certainly left us all with food for thought on the OTC landscape in a world of digital!

As an official announcement, now the conference has ended, we hope to see you next year in… BARCELONA for our 29th European OTC conference #NHOTC18. Auf Wiedersehen or should I say… Adios!”

Screen Shot 2017-04-24 at 12.03.52

#NHOTC17: Day 1

OTCINACTION

Our 28th European OTC INSIGHT conference, centred on the theme of Making the Most of New Technology, took place in Munich last week. Following Nicholas’ annual overview of the global OTC market, and what’s ahead, there was a packed schedule of presentations on topics including the future of digital OTC and what we see technology providers delivering now and in the future.

IMG_2161

Nicholas Hall kicked off proceedings on Day 1

Richard Learwood of PGT Healthcare got our brains into gear on the morning of Day 1 with a thought-provoking discussion on accelerating growth in consumer healthcare, and this was shortly followed by Dr Dennis Ballwieser, of Wort & Bild, who shed some light on the future of partnerships in digital publishing and how digital is affecting the print industry in healthcare.

Leading into the lunch session, Infirst Healthcare’s Manfred Scheske led a thought-provoking session, which showed us how our industry is extremely focused on Strategic Growth and Share Grab, but needs to step up its ambition to shape market conditions and to grow markets. He addressed the increasing number of line extensions, which have successfully grown many big OTC brands, but less and less new products offer meaningful news, and patients and pharmacists and the general public are increasingly irritated and confused by the tidal wave of ‘plus’, ‘forte’, ‘extra’, ‘ultra’, ‘max’, ‘advance’, ‘extra advance’, ‘rapid’, ‘express’, etc.” Certainly food for the mind before we ate our lunch!

After lunch, Alison Hartley from Sanofi got the conference back into swing with a presentation on Digital Excellence, explaining that content is key but distribution is queen! Alison also delved into the many ways that digital has enabled us to do things we wouldn’t have been able to do without digital media.

Alison

Alison Hartley focuses on Digital Excellence in OTC

Our very own Monica Feldman also enlightened us on e-connecting the revenue dots, explaining that VIRAL = REVENUE and to have this you must have humour, heart, brains and guts. Trevor Gore of Maestro Consulting took to the stage as our final speaker on Day 1, alongside David Taylor, leading us to contemplate whether technology is helping us or making us addicts? Trevor certainly lifted spirits with his stand up presenting style!

Monica

Our Global Director of Client Services, Monica Feldman

Look out for more Dashboard blog content coming soon, including Day 2 of the conference and the Nicholas Hall Awards. As an official announcement now the conference has ended, we hope to see you next year in… Barcelona, for our 29th European OTC conference #NHOTC18.

Nielsen-CHPA Survey on OTC Allergy Trends

OTCinActionheader

Coughing, sneezing, a runny nose and itchy eyes are just some of the symptoms of seasonal or chronic allergies, one of the most common ailments impacting the lives of Americans today, according to a new white paper on Rx-to-OTC allergy switches, produced by Nielsen and the US OTC industry association, Consumer Health Products Association (CHPA).

In 2015, 27.8% of Americans suffered from allergies, which translates to approximately 69 million adults, and 89 million people overall. Since 2009, a number of ingredients, including antihistamines and intranasal steroids that were only available Rx, have now switched to OTC, giving consumers more options to treat their allergies.

While there is abundant data to show that allergy OTC sales have grown significantly owing to the increasing number of brands available, there haven’t been many studies conducted to understand how these Rx-to- OTC switches have benefitted allergy sufferers.

Nielsen’s latest report assesses the consumer benefits of allergy Rx-OTC switches to help gain an understanding of allergy-suffering consumers and how having access to more oral and nasal OTC medications has contributed to their financial and personal wellbeing.

Allergy photo

The survey is made up of data based around allergy patient visits, the number of prescriptions written by month, the costs for each, and corresponding insurance-related costs. Nielsen also provided data on allergy sufferer penetration, their buying behaviour, and how each consumer treats their ailment. 
A survey was also fielded to 2,000 adult allergy sufferers to better understand their treatment routine and overall satisfaction with their medication options.

The report found that more and more Americans are suffering from allergies. Over the time period analysed, the number of individuals who stated that they suffer from allergies has increased. There are approximately 9.7mn more allergy sufferers today than there were
 in 2010.

There has also been a clear shift to OTCs. 
The number of allergy sufferers taking OTCs has increased, while 
at the same time the number of sufferers taking prescription medications has declined. Just as importantly, the report also found that allergy sufferers who take OTCs are highly satisfied with the medication options available to them.

The report is available to download here.

American Health Care Act unveiled

OTCinActionheader

The Trump administration’s long-awaited replacement plan for the Affordable Care Act has now been released. The American Health Care Act (AHCA) was developed in conjunction with the White House and Senate Republicans.

Despite the replacement plan being released, two big questions still remain unanswered. How many people will the plan cover and how much will it cost?

It is likely that the plan will cover fewer people than the Affordable Care Act currently does, but exactly how many has not been specified. The Congressional Budget office has not yet scored the legislation, so the current costs are unknown.

ACA

Early assessment of the replacement act seems to indicate that:

  • Some of Obamacare’s signature features have been entirely eradicated, such as the tax on people who don’t purchase healthcare. Other protections, including the ban on discriminating in regard to people with pre-existing conditions and the provision that allows young adults to stay on their parents’ plan until age 26, would survive
  • The plan maintains the Medicaid expansion – the Affordable Care Act has expanded Medicaid to cover millions of low-income Americans
  • According to critics, the replacement plan benefits people who are healthy and high-income and disadvantages those who are sick and lower income. The replacement plan would make several changes to what health insurers can charge enrolees who purchase insurance on the individual market, as well as changing what benefits their plans must cover
  • The bill looks a lot more like Obamacare than previous drafts. A curious thing has happened to the Republican replacement plan as it has evolved through multiple drafts; it has begun to look more and more like Obamacare itself.

Nicholas Hall will be bringing his regional conference series to North America in 2017, with our 1st North American OTC Conference, being held in the OTC hub of New Jersey on 27-28 June 2017. You can join us for a gloves-off discussion on how recent political changes in the US will affect future healthcare. Early Bird rates are available until the end of March only! Please contact lianne.hill@NicholasHall.com now to find out more or register your interest.

New advice says eat 10 fruit & veg per day

OTCinActionheader

A study by Imperial College London has suggested we should eat 10 portions of fruit & vegetables a day. The study said that such eating habits could prevent 7.8 million premature deaths each year. The study also identified particular fruit & vegetables that reduced the risk of cancer and heart disease.

A portion counts as 80g (3oz) of fruit or vegetables, which is equal to a small banana, a pear, or three heaped tablespoons of spinach or peas. The findings were based on pooled data on 95 separate studies, involving the eating habits of two million people.

Lower risk of cancer was linked to eating green vegetables such as spinach and kale, yellow vegetables and cauliflower. Lower risk of heart disease and strokes was linked to eating apples, pears, citrus fruits and leafy greens.

The results, published in the International Journal of Epidemiology, also assessed the risk of dying before your time. Compared with eating no fruit or veg a day, it showed:

  • 200g cut the risk of cardiovascular disease by 13% while 800g cut the risk by 28%
  • 200g cut the risk of cancer by 4%, while 800g cut the risk by 13%
  • 200g cut the risk of a premature death by 15%, while 800g cut the risk by 31%

Fresh fruit stand with boysenberries, raspberries, cherries and grapes

The researchers do not know if eating even more fruit & vegetables than the newly suggested 10 portions would have even greater health benefits, as there is little evidence out there to review.

Dr Dagfinn Aune, one of the researchers, said: “Fruit & vegetables have been shown to reduce cholesterol levels, blood pressure and to boost the health of our blood vessels and immune system.” He continued: “This may be due to the complex network of nutrients they hold, including many antioxidants, which may reduce DNA damage and lead to a reduction in cancer risk.”

However the study also said that the benefits of this would be hard to integrate as many people struggle to even eat the five a day (400g) which is recommended by the World Health Organization. In the UK, only about one in three people eat this recommended portion, showing the huge potential for VMS marketers in terms of targeting their supplements at people that don’t eat their 10 fruit & veg a day.